NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-17-041 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.
Funding Opportunity PA-17-042 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory and developmental research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations
Funding Opportunity RFA-AG-18-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support an initial series of activities over a 3-year period to build the foundation for enhanced collaborations across NIA's 6 centers programs. These collaborations are intended to leverage NIA's substantial investments by fostering the development of novel interdisciplinary efforts in aging research. This opportunity will provide resources to build additional infrastructure and establish specific collaborative activities that could include, but are not limited to, information and data exchange, meetings and conferences, pilot studies, research opportunities for beginning investigators, visiting scholar programs, dissemination, and other collaborative efforts. The successful awardee will involve all 6 centers programs.
Funding Opportunity PAR-17-040 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities that enhance the diversity of the biomedical workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences and courses for skills development.
Funding Opportunity PAR-17-037 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
Funding Opportunity PAR-17-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
Funding Opportunity RFA-AG-17-059 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and related dementia (ADRD). Studies may be observational treatment studies or pragmatic clinical trials. This FOA will support pilot research to test the feasibility of interventions (R21 phase) that, if successful, can transition to an R33 phase for implementation of pragmatic trials. The transition from the R21 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the criteria that are specified in the R21 phase.
Funding Opportunity RFA-AG-17-060 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and related dementia (ADRD). This FOA will support advanced-stage observational treatment studies or pragmatic clinical trials.
Funding Opportunity RFA-ES-17-002 from the NIH Guide for Grants and Contracts. The purpose of the ViCTER program is to foster and promote transdisciplinary collaborations and/or translational research efforts among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers and other individuals with expertise relevant to environmental health who have come together in common interest around a particular environmental stressor(s) of interest. A key component of the Virtual Consortia Program is the stimulation of innovative and novel cross-disciplinary and/or translational collaborations that can be more difficult to achieve in a typical R01 application, thereby accelerating the public health impact of the research.
Notice NOT-HL-16-459 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-16-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to initiate and implement a network of participating clinical centers to perform pilot and feasibility studies of therapies to slow or reverse the progression of chronic kidney disease (CKD) in children. This FOA invites applications for the Participating Clinical Centers (PCCs) and runs in parallel with a separate FOA that invites applications for the Data Coordinating Center (DCC) (RFA-DK-16-035). These pilot studies will seek to optimize critical elements of a full-scale randomized control trial design - the most promising study question, agent(s), target population, dosing, data collection, and appropriate outcomes. Applicants must propose two trials to be conducted sequentially over the funding period. One trial will be to lower serum uric acid levels, while the other can be an appropriately justified study question of the applicant's choosing. When applicable, clinical site investigators may enlist industry collaboration to achieve the goals of the network. The ultimate goal of this FOA is to obtain the necessary information to design and implement one or more full-scale randomized controlled clinical trials of therapies to reduce morbidity in children with CKD.
Funding Opportunity RFA-DK-16-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to initiate and implement a network of participating clinical centers and a data coordinating center to perform pilot and feasibility studies of therapies to slow or reverse the progression of chronic kidney disease (CKD) in children. This FOA invites applications for the Data Coordinating Center (DCC) and runs in parallel with a separate FOA that invites applications for the Participating Clinical Centers (PCCs) (RFA-DK-16-018). These pilot studies will seek to optimize critical elements of a full-scale randomized control trial design - the most promising study question, agent(s), target population, dosing, data collection, and appropriate outcomes. Applicants must propose two trial designs to be conducted sequentially over the funding period. One trial will be to lower serum uric acid levels, while the other can be an appropriately justified study question of the applicant's choosing. The ultimate goal of this FOA is to obtain the necessary information to design and implement one or more full-scale randomized controlled clinical trial of therapies to reduce morbidity in children with CKD.
Funding Opportunity PAR-17-035 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.
Funding Opportunity PAR-17-036 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.
Funding Opportunity PAR-17-034 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.
Funding Opportunity PAR-17-039 from the NIH Guide for Grants and Contracts. This FOA invites exploratory comparative biology research projects assessing how different animal species respond to challenges and damage to cellular physiology pathways that might influence the onset of Alzheimer's and other neurodegenerative diseases as well as resilience to them, such as adaptation to stress, macromolecular damage, proteostasis and stem cell function and regeneration.
Notice NOT-NS-17-005 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-17-056 from the NIH Guide for Grants and Contracts. This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the APOE2Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/cross talk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.
Funding Opportunity RFA-AG-17-051 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of molecular machines that are responsible for exosome biogenesis and the secretion of exosomal cargo molecules in AD.